{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:22:50Z","timestamp":1778498570975,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Research Foundation for Dementia of Osaka","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]},{"name":"Teijin Pharma Limited","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>\u03b1-Synuclein oligomers are thought to play an important role in the pathogenesis of dementia with Lewy bodies (DLB). There is no effective cure for DLB at present. Previously, we demonstrated that in APP- and tau-transgenic mice, oral or intranasal rifampicin reduced brain A\u03b2 and tau oligomers and improved mouse cognition. In the present study, we expanded our research to DLB. Rifampicin was intranasally administered to 6-month-old A53T-mutant \u03b1-synuclein-transgenic mice at 0.1 mg\/day for 1 month. The mice displayed memory impairment but no motor deficit at this age, indicating a suitable model of DLB. \u03b1-Synuclein pathologies were examined by the immunohistochemical\/biochemical analyses of brain tissues. Cognitive function was evaluated by the Morris water maze test. Intranasal rifampicin significantly reduced the levels of [pSer129] \u03b1-synuclein in the hippocampus and \u03b1-synuclein oligomers in the visual cortex and hippocampus. The level of the presynaptic marker synaptophysin in the hippocampus was recovered to the level in non-transgenic littermates. In the Morris water maze, a significant improvement in spatial reference memory was observed in rifampicin-treated mice. Taken together with our previous findings, these results suggest that intranasal rifampicin is a promising remedy for the prevention of neurodegenerative dementia, including Alzheimer\u2019s disease, frontotemporal dementia, and DLB.<\/jats:p>","DOI":"10.3390\/ijms22168453","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T08:01:42Z","timestamp":1628236902000},"page":"8453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Nasal Rifampicin Improves Cognition in a Mouse Model of Dementia with Lewy Bodies by Reducing \u03b1-Synuclein Oligomers"],"prefix":"10.3390","volume":"22","author":[{"given":"Tomohiro","family":"Umeda","sequence":"first","affiliation":[{"name":"Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-5741","authenticated-orcid":false,"given":"Yukari","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takami","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1353-8020(13)70017-8","article-title":"\u03b1-Synucleinopathy phenotypes","volume":"20","author":"McCann","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108843","DOI":"10.1016\/j.biopha.2019.108843","article-title":"Progress of immunotherapy of anti-\u03b1-synuclein in Parkinson\u2019s disease","volume":"115","author":"Wang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","article-title":"Alpha-synuclein oligomers: A new hope","volume":"134","author":"Roberts","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_4","first-page":"791","article-title":"Soluble endogenous oligomeric \u03b1-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk","volume":"10","author":"Kayed","year":"2020","journal-title":"J. Park. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/aww042","article-title":"Rifampicin is a candidate preventive medicine against amyloid-\u03b2 and tau oligomers","volume":"139","author":"Umeda","year":"2016","journal-title":"Brain"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","article-title":"Rifampicin reduces \u03b1-synuclein in a transgenic mouse model of multiple system atrophy","volume":"19","author":"Ubhi","year":"2008","journal-title":"Neuroreport"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.trci.2018.06.012","article-title":"Intranasal rifampicin for Alzheimer\u2019s disease prevention","volume":"4","author":"Umeda","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41380-020-00864-7","article-title":"Advances in the field of intranasal oxytocin research: Lessons learned and future directions for clinical research","volume":"26","author":"Quintana","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","article-title":"Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of \u03b1-synucleinopathy","volume":"138","author":"Singh","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/bbrc.1994.2428","article-title":"Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid \u03b2 Protein in Vitro","volume":"204","author":"Tomiyama","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1074\/jbc.271.12.6839","article-title":"Inhibition of Amyloid \u03b2 Protein Aggregation and Neurotoxicity by Rifampicin","volume":"271","author":"Tomiyama","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"The DARAD Study Group: A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer\u2019s disease: The DARAD trial","volume":"28","author":"Molloy","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/brain\/awz142","article-title":"Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease","volume":"142","author":"Nicoll","year":"2019","journal-title":"Brain"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/acn3.51048","article-title":"The A4 study: \u03b2-amyloid and cognition in 4432 cognitively unimpaired adults","volume":"7","author":"Insel","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The Amyloid-\u03b2 Oligomer Hypothesis: Beginning of the Third Decade","volume":"64","author":"Cline","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/jnc.15007","article-title":"A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer\u2019s brain","volume":"154","author":"Li","year":"2020","journal-title":"J. Neurochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000477343","article-title":"Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study","volume":"7","author":"Iizuka","year":"2017","journal-title":"Dement. Geriatr. Cogn. Disord. Extra"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","article-title":"Rifampicin Inhibits \u03b1-Synuclein Fibrillation and Disaggregates Fibrils","volume":"11","author":"Li","year":"2004","journal-title":"Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","article-title":"Efficacy and safety of rifampicin for multiple system atrophy: A randomised, double-blind, placebo-controlled trial","volume":"13","author":"Low","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1474-4422(14)70022-5","article-title":"Rifampicin for multiple system atrophy","volume":"13","author":"Wenning","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/978-981-32-9358-8_27","article-title":"Tau Oligomers","volume":"1184","author":"Maeda","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnmol.2020.00155","article-title":"Understanding the Pathophysiological Actions of Tau Oligomers: A Critical Review of Current Electrophysiological Approaches","volume":"13","author":"Hill","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurobiolaging.2017.08.007","article-title":"Sigma-1 receptor knockout increases \u03b1-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra","volume":"59","author":"Hong","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108889","DOI":"10.1016\/j.cbi.2019.108889","article-title":"Rifampicin activates AMPK and alleviates oxidative stress in the liver as mediated with Nrf2 signaling","volume":"315","author":"Lee","year":"2020","journal-title":"Chem. Interact."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2011.04.019","article-title":"Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation","volume":"1395","author":"Bi","year":"2011","journal-title":"Brain Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Acu\u00f1a, L., Hamadat, S., Corbal\u00e1n, N.S., Gonz\u00e1lez-Liz\u00e1rraga, F., Dos-Santos-Pereira, M., Rocca, J., D\u00edaz, J.S., Del-Bel, E., Papy-Garc\u00eda, D., and Cheh\u00edn, R.N. (2019). Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by alpha\u03b1-Synuclein Fibrillary Aggregates. Cells, 8.","DOI":"10.3390\/cells8080776"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liang, Y., Zheng, D., Peng, S., Lin, D., Jing, X., Zeng, Z., Chen, Y., Huang, K., Xie, Y., and Zhou, T. (2020). Rifampicin attenuates rotenone-treated microglia inflammation via improving lysosomal function. Toxicol. Vitr., 63.","DOI":"10.1016\/j.tiv.2019.104690"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer\u2019s disease: Current evidence and future directions","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3389\/fphar.2018.00867","article-title":"Suppression of Presymptomatic Oxidative Stress and Inflammation in Neurodegeneration by Grape-Derived Polyphenols","volume":"9","author":"Herman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3389\/fnins.2019.01036","article-title":"Potential Neuroprotective Treatment of Stroke: Targeting Excitotoxicity, Oxidative Stress, and Inflammation","volume":"13","author":"Yang","year":"2019","journal-title":"Front. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.brainres.2003.10.012","article-title":"Rifampicin attenuates brain damage in focal ischemia","volume":"996","author":"Yulug","year":"2004","journal-title":"Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1523\/JNEUROSCI.5825-09.2010","article-title":"A Mouse Model of Amyloid Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo","volume":"30","author":"Tomiyama","year":"2010","journal-title":"J. Neurosci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:41:36Z","timestamp":1760164896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":36,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22168453"],"URL":"https:\/\/doi.org\/10.3390\/ijms22168453","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]}}}